Second‐Line Therapy Following Osimertinib in Metastatic EGFR ‐Mutated Non‐Small‐Cell Lung Cancer at an Academic Medical Center
Cancer Reports · 2026
DOI: 10.1002/cnr2.70693 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2026. Verfasst von Michael Rafizadeh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Aniline Compounds, Acrylamides. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Background
FLAURA2 demonstrated that adding chemotherapy to osimertinib improved overall survival compared with osimertinib monotherapy in metastatic epidermal growth factor receptor ‐mutated ( EGFR ‐mut) non‐small‐cell lung cancer (NSCLC). Notably, only 60% of patients in the osimertinib monotherapy arm received second‐line therapy after discontinuing first‐line osimertinib.
Aims
We hypothesized that a higher proportion of patients on osimertinib monotherapy receive second‐line therapy at academic medical centers in the United States (US). Methods and Results This is a retrospective cohort study of 115 patients with metastatic EGFR ‐mut NSCLC treated with first‐line osimertinib monotherapy at an academic medical center in the United States from February 2018 to July 2024. Analyses included Kaplan–Meier survival estimation, log‐rank test, multivariate Cox regression, Wilcoxon rank‐sum test, and Fisher's exact test. Most patients were female (74%) and had a history of never‐smoking (69%); 50% were Asian, and 93% of patients had adenocarcinoma histology. The median time to treatment failure (TTF) for all patients on first‐line osimertinib was 25.3 months (95% CI: 18.6–37.5). The median TTF was 15.7 months (CI: 13.1–22.0) for patients with TP53 ‐mut disease and 42.2 months (CI: 36.9–NR) for patients with TP53 wild‐type tumors (log‐rank test, p < 0.001). Of the 115 total patients, 66 (57.4%) discontinued first‐line osimertinib. Of these 66 patients, 26 (39.4%) either died or pursued hospice. Forty (60.6%) of the 66 patients experienced progression of disease and subsequently received second‐line therapy.
Conclusion
Only 61% of patients with metastatic EGFR ‐mut NSCLC received second‐line therapy after osimertinib at our institution, similar to the second‐line therapy rates in the control arm of FLAURA2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
- Department of Population Health Sciences, Weill Cornell Medicine, New York, New York, USA.
- Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
ORCID-Profile: Michael Rafizadeh, Stephanie Bogdan, Christine Garcia, Kathy Zhou, Bobak Parang
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Rafizadeh, M., Bogdan, S., Lee, J., Garcia, C., Saxena, A., Zhou, K., & Parang, B. (2026). Second‐Line Therapy Following Osimertinib in Metastatic EGFR ‐Mutated Non‐Small‐Cell Lung Cancer at an Academic Medical Center. Cancer Reports. https://doi.org/10.1002/cnr2.70693
Vancouver
Rafizadeh M, Bogdan S, Lee J, Garcia C, Saxena A, Zhou K, et al. Second‐Line Therapy Following Osimertinib in Metastatic EGFR ‐Mutated Non‐Small‐Cell Lung Cancer at an Academic Medical Center. Cancer Reports. 2026. doi:10.1002/cnr2.70693
BibTeX
@article{Rafizadeh2026,
author = {Rafizadeh, Michael and Bogdan, Stephanie and Lee, Jonathan and Garcia, Christine and Saxena, Ashish and Zhou, Kathy and Parang, Bobak},
title = {Second‐Line Therapy Following Osimertinib in Metastatic EGFR ‐Mutated Non‐Small‐Cell Lung Cancer at an Academic Medical Center},
journal = {Cancer Reports},
year = {2026},
doi = {10.1002/cnr2.70693}
}
EUVIMED